Rheumatology 2001; 40: 1405-1412
© 2001 British Society for Rheumatology
Original Papers |
An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study
Centre for Rheumatology, Bloomsbury Rheumatology Unit, Department of Medicine, University College London, London W1T 4NJ, UK
Objective. To establish the correlation between lupus nephritis-associated autoantibody levels and the presence/activity of lupus nephritis and global disease activity using cross-sectional data in patients with systemic lupus erythematosus (SLE).
Methods. Disease activity was assessed using the British Isles Lupus Assessment Group (BILAG) index. Antibody levels against single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), histones, nucleosomes and heparan sulphate (HS) were analysed by ELISA in SLE patients with (n=11) and without (n=22) nephritis and in normal controls (n=21). Antibody subclasses were also analysed.
Results. Higher levels of anti-dsDNA and anti-HS antibodies were found in patients with lupus nephritis, the level of anti-HS antibodies correlating with the BILAG renal score. Predominant subclasses were IgG1 and IgG3 for dsDNA antibodies, IgG2 for anti-nucleosome antibodies, and IgG2 and IgG3 for anti-HS antibodies.
Conclusion. Correlation was demonstrated between antibodies to dsDNA, ssDNA, histones, nucleosomes and HS. There is a strong correlation between the level of anti-HS antibodies and disease activity in patients with lupus nephritis as measured by BILAG.
KEY WORDS: Systemic lupus erythematosus, Serum autoantibodies, Nephritis.
Correspondence to: C. T. Ravirajan, Bloomsbury Rheumatology Unit, Centre for Rheumatology, University College London, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G Moroni, A Radice, G Giammarresi, S Quaglini, B Gallelli, A Leoni, M L Vecchi, P Messa, and R A Sinico Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis Ann Rheum Dis, February 1, 2009; 68(2): 234 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Burling, J. Ng, H. Thein, J. Ly, M.R. Marshall, and P. Gow Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort Lupus, October 1, 2007; 16(10): 830 - 837. [Abstract] [PDF]
|
|
|
|
 |
|
 D. A. Isenberg, J. J. Manson, M. R. Ehrenstein, and A. Rahman Fifty years of anti-ds DNA antibodies: are we approaching journey's end? Rheumatology, July 1, 2007; 46(7): 1052 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.M. Stinton, S.G. Barr, L.A. Tibbles, S. Yilmaz, A. Sar, H. Benedikttson, and M.J. Fritzler Autoantibodies in lupus nephritis patients requiring renal transplantation Lupus, June 1, 2007; 16(6): 394 - 400. [Abstract] [PDF]
|
|
|
|
|
|
G S Alarcon, J Calvo-Alen, G McGwin Jr, A G Uribe, S M A Toloza, J M Roseman, M Fernandez, B J Fessler, L M Vila, C Ahn, et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time Ann Rheum Dis, September 1, 2006; 65(9): 1168 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Prasad, D Ibanez, D Gladman, and M Urowitz Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus Lupus, May 1, 2006; 15(5): 285 - 291. [Abstract] [PDF]
|
|
|
|
|
|
D. A. Isenberg, A. Rahman, E. Allen, V. Farewell, M. Akil, I. N. Bruce, D. D'Cruz, B. Griffiths, M. Khamashta, P. Maddison, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus Rheumatology, July 1, 2005; 44(7): 902 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Isenberg Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus? Lupus, November 1, 2004; 13(11): 881 - 885. [Abstract] [PDF]
|
|
|
|
|
|
L. M. Vila, G. S. Alarcon, G. McGwin Jr, A. W. Friedman, B. A. Baethge, H. M. Bastian, B. J. Fessler, and J. D. Reveille Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations Rheumatology, March 1, 2004; 43(3): 358 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A E M van Nieuwenhuijze, T van Lopik, R J T Smeenk, and L A Aarden Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus Ann Rheum Dis, January 1, 2003; 62(1): 10 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Rahman and F Hiepe Anti-DNA antibodies - overview of assays and clinical correlations Lupus, December 1, 2002; 11(12): 770 - 773. [Abstract] [PDF]
|
|